New Drug-Resistant TB Medicines Need to be Affordable - MSF

The results of a clinical trial, published in the New England Journal of Medicine, has shown that a new six-month regimen for drug-resistant tuberculosis (DR-TB) is safer, more convenient, and much more effective than the standard-of-care treatments, Daniel Steyn of GroundUp reports.

The trial tested three different regimens against the standard of care used in Belarus, South Africa, and Uzbekistan. It found one to be the most effective and safe: a combination of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM).

But concerns remain about the affordability and accessibility of BPaLM. The Global Drug Facility, which works to facilitate access to affordable TB treatment, has provided a lowest global price of U.S.$600 (R10,300), but Médecins Sans Frontières says the price should be below U.S.$500 (R8,600) to be affordable.

DR-TB is a form of tuberculosis that does not respond to the drugs normally used to treat TB. In South Africa, about 14,000 people contract DR-TB every year.


A South African patient prepares to take her medication for drug-resistant TB (file photo).

Follow AllAfrica

AllAfrica publishes around 500 reports a day from more than 100 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.